

As part of a multi-site clinical trial of the <https://clinicaltrials.gov/ct2/show/study/NCT02441416> of the Maternal Opioid Treatment: Human Experimental Research

Maternal Opioid Treatment: Human Experimental Research
Hendree Jones, Ph.D.

Though clearly beneficial, the use of methadone during pregnancy remains controversial in part due to the

Coordinating Center
Amelia Arria, Ph.D.

JHUSOM is the Lead Site for this study involving several sites within the United States with two international sites in the EU and

Maternal Opioid Treatment: Human Experimental Research
Gabriele Fischer, M.D.

The Vienna team skilled in addiction medicine, psychiatry, pediatrics, obstetrics, neonatology, and contraindications

***Maternal Opioid Treatment: Human
Sarah H. Heil, Ph.D.***

The University of Vermont (UVM) site proposes to participate in the multi-site trial led by the Johns Hopkins

***Maternal Opioid Treatment: Human Experimental Research
Karol Kaltenbach, Ph.D.***

Thomas Jefferson University (TJU) proposes to participate in the multi-site trial led by the Johns Hopkins

***Maternal Opioid Treatment: Human Experimental Research
Peter R. Martin, M.D.***

The efficacy of buprenorphine to produce less neonatal abstinence signs (NAS) in the neonate, compared

***Maternal Opioid Treatment: Human
Susan M. Stine, M.D., Ph.D.***

The Wayne State University (WSU) Site proposes to participate in the multi-site trial led by the Johns Hopkins

***Maternal Opioid Treatment: Human
Barry M. Lester, Ph.D.***

The Johns Hopkins School of Medicine (JHUSOM), the Lead Site for this study has a team trained in ad

***Maternal Opioid Treatment: Human Experimental Research
Peter Selby, M.D.***

St. Joseph